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Abstract
The study on the interaction of human serum albumin (HSA) with three widely used 
drugs (diclofenac sodium (DIC), furosemide (FUR) and dexamethasone phosphate 
(DEX)) was investigated by fluorescence method. Fluorescence emission spectra 
of HSA in presence of the studied drugs was recorded at excitation wavelength 
278 nm and showed that the studied drugs act as quenchers. A decrease in 
fluorescence emission at 340 nm was attributed to changes in environment of the 
protein fluorophore caused due to presence of the ligand.  
The modified Stern–Volmer equation was used as a mathematical model to 
calculate the binding constants between the drug and HSA. The binding constants 
for the studied drugs with HSA were found inversely related with temperature.
The thermodynamic parameters, the changes of standard Gibbs free energy (ΔG°), 
enthalpy change (DH°) and entropy change (DS°) for the drug-HSA interaction 
were calculated according to van't Hoff equation. Among the thermodynamic 
parameters, the values of ΔG° were: -25.83, -25.29 and -25.09 kJ/mol for 
the drugs DIC, FUR and DEX, respectively, and the values of ΔH° and ΔS° were 
negative suggested that the hydrogen bonding and van der Waals forces were the 
predominant intermolecular forces in stabilizing the drug-HSA complex formed. 
The effect of pH on the binding of the studied drugs to human serum albumin 
in phosphate buffer solutions (pH 6.0-8.0) has been investigated in this study. 
The results showed that the binding of each studied drug was decreased with 
pH studied and the results were attributed according to the ionic forms of both 
protein and drug in the pH range studied.
Finally, the distances between the donor (HSA) and the acceptor (drug) 
were estimated to be 2.98, 3.52 and 5.30 nm for the drugs DIC, FUR and DEX, 
respectively,  based on Förster’s resonance energy transfer theory (FRET).
Keywords : Thermodynamic parameters;  Human serum albumin; Fluorescence 
quenching;  Drug interaction;   Modified Stern-Volmer;   Förster’s theory
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Introduction
Human serum albumin (HSA) is an abundant plasma protein, 
which attracts great interest in the pharmaceutical industry since 
it can bind a remarkable variety of drugs impacting their delivery 
and efficacy and ultimately altering the drug’s pharmacokinetic 
and pharmacodynamic properties. HSA being the most abundant 
protein of blood plasma, and has a limited number of high-affinity 
binding sites. 
HSA comprises three homologous domains that assemble to 
form a heart-shaped molecule. Each domain is a product of 
two subdomains that possess common structural motifs. The 
principal regions of ligand binding to human serum albumin 
are located in hydrophobic cavities in subdomains IIA and 
IIIA, which exhibit similar chemistry. The structure explains 
numerous physical phenomena and should provide insight into 
future pharmacokinetic and genetically engineered therapeutic 
applications of serum albumin [1].
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The three-dimensional structure of human serum albumin has 
been determined crystallographically to a resolution of 2.8 Å. 
the structural information of the affinity binding sites is useful 
when designing new drugs whether the aim is to avoid binding 
to HSA, or to make use of its depot function [2]. Sudlow et al. 
did pioneering studies in this field by using a fluorescent probe 
displacement method in 1975 and 1976 [3,4]. With this method 
they showed through a screening, that there are two specific 
drug binding sites on HSA, namely, site I (also called the warfarin 
binding site) and site II (the benzodiazepine binding site). 
Current crystallographic studies have proved that the majority 
of drugs bind to two main binding sites of high and low affinities 
[5-8].
 Yang et al. proposed that interactive association of drugs binding 
to HSA usually occurs in site I of HSA, namely,  II A subdomain . 
Site I is a big hydrophobic cavity that is possible to hold several 
drugs at the same time [9,10]. Site 1 is a preformed binding 
pocket within the core of subdomain IIA, which comprises six 
helices of the subdomain and a loop-helix feature (residues 148–
154). The interior of the pocket is hydrophobic, predominantly 
delimited by residues Trp214, Leu219, Phe223, Leu238, His242, 
Leu260, Ile264, Ser287, Ile290, and Ala291. However, it also 
contains two clusters of polar residues, an inner cluster of 
residues toward the bottom of the pocket (Tyr150, His242, 
Arg257) and an outer cluster at the pocket entrance composed of 
Lys195, Lys199, Arg218, and Arg222 (Figure 1). The large binding 
cavity is comprised of a central zone from which three distinct 
compartments extend [9]. 
On the other hand, drugs have two forms in circulation, namely, 
bound or unbound to plasma proteins. The unbound drugs can 
passively diffuse through the barriers constituted by endothelial 
cells into the organs where they are metabolized, biliary excretion 
or glomerular filtration in kidney [11-13]. The unbound drugs can 
also be distributed intracellularly via specific transport systems. 
Only free drug molecules interact with therapeutic targets to 
produce therapeutic effects [11,14]. In most instances, the 
unbound drug concentration of drug in the tissue depends on the 
unbound drug concentration in the plasma [11]. Thus, HSA–drug 
interactions represent an important factor to understand the 
pharmacokinetics and pharmacological effects of drugs [15-19]. 
Many drugs and other bioactive small molecules bind reversibly 
to albumin and other serum components, which then function as 
carriers. Serum albumin often increases the apparent solubility 
of hydrophobic drugs in plasma and modulates their delivery to 
cell in vivo and in vitro [20]. 
Diclofenac (DIC)
 2-(2,6-dichloroanilino) phenylacetic acid (Figure 2a) is a non-
steroidal-anti-inflammatory-drug that is used as an active 
compound in analgesic, antipyretic, anti-rheumatic medicaments. 
It is used in the form of sodium or potassium salt [20]. 
Dexamethasone (DEX)
 11b,16a)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-
diene-3,20-dione (Figure 2b) is a potent synthetic member of 
the glucocorticoid class of steroid hormones. It acts as an anti-
inflammatory and immunosuppressant. Its potency is about 20 
– 30 times that of hydrocortisone and 4–5 times of prednisone. 
It is a synthesized corticosteroid compound that has been widely 
used in clinical treatment for Addison’s disease, systemic lupus 
erythematosus, periarteritis nodosa and other autoimmune 
disease [21]. 
Furosemide (FUR)
 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid (Figure 2c) is 
primarily used for the treatment of hypertension and edema. 
It is the first-line agent in most people with edema caused by 
congestive heart failure. It is also used for hepatic cirrhosis, 
renal impairment, nephrotic syndrome, in adjunct therapy for 
cerebral or pulmonary edema where rapid diuresis is required 
(IV injection), and in the management of severe hypercalcemia in 
combination with adequate rehydration [22].
In the present study, we focused on the interaction of three widely 
used drugs (Diclofenac sodium, dexamethasone and furosemide) 
Figure 1 The binding environment of ligand site in IIA subdo-
main of HSA.
The binding environment of ligand site in IIA subdomain 
of HSA.
Figure 1
 a- Diclofenac Sodium b- Dexamethasone (DEX)
c- Furosemide (FUR)
 
Figure 2 Chemical structures of the drugs studied. Chemical structures of the drugs studied.Figure 2
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with HSA in vitro at different temperatures (20-40°C) at pH 7.0 
and at different pHs (6.0-8.0) at the same temperature (25°C), via 
spectrofluorimetric method. Consequently, we made an analysis 
and interpretation of the fluorescence data. The accurate and 
comprehensive data accumulated here may help to elucidate 
the binding mechanism between these drugs and HSA. It may 
contribute to an enhanced understanding of the transportation, 
distribution, metabolism, and drug efficacy of these drugs in 
blood. Also, it may play valuable insights in binding parameters, 
such as the binding constant, number of binding sites, binding 
force, and binding distance between the interacting species.  
Materials and Methods
Pure drug samples were obtained as gift from the faculty of 
medicine at the Islamic University of Gaza. HSA (<0.05 % fatty 
acid) was purchased from Sigma Chemical Co. (St. Louis, MO). 
All other substances used were of analytical grade and were 
used as received without further purification. HSA solutions 
were prepared in the phosphate buffer solutions (20 mM) of the 
desired pH (6.0 - 8.0) and stored in the dark at 4°C. The pH was 
checked with a digital pH meter (RIDAO PHS-2C). All reagents 
used were of analytical reagent grade and distilled water was 
used throughout the experiments. 
Human serum albumin stock solutions (in phosphate buffer 
solution at the desired pH) were prepared directly prior to 
experiment and the final concentration of 15 μM was confirmed 
by absorbance measurement using the absorption coefficient at 
maximum wavelength (ε278 = 37000 M–1cm–1) and then diluted 
to 1.5 μM using the same buffer solution. After addition of each 
drug sample the fluorescence signals were measured within 40 
seconds, separated by a 20 s break for the next sample injection. 
Drug- HSA interaction
In order to determine the binding parameters of the drugs 
with HSA, 2 mL of 1.5 µM HSA solution was taken in a quartz 
cuvette. The bandwidth for measuring emission was 5 nm. The 
temperature of sample was kept by recycled water throughout 
the experiment. Then, a successive 20 µL injections of the drug 
stock solution of 50 µM  were added to protein solution. The final 
drug concentration was in the range of 0 - 0.42 µM. Fluorescence 
spectra were recorded in the range of 300 - 500 nm after 
excitation at 278 nm in each case. Intrinsic fluorescence of HSA 
was measured at 340 nm. Fluorescence spectra were measured 
with a Perkin Elmer LS50B spectrofluorometer interfaced to a 
computer for data collection and analysis, using 10 nm/10 nm slit 
widths. The fluorescence emission spectra of HSA in the absence 
and presence of increasing amounts of the drugs under study 
were recorded. All experiments at four different temperatures 
(in the range of 20-45°C) were performed at pH 7.0. The sample 
temperature was maintained by recycling water from a super 
thermostatic water tank (SYC-15) throughout the experiments.
Data analysis
The association constant describing the ligand – protein 
bond strength was commonly calculated from curve fitting to 
experimental points. Some researchers fit the equation described 
by Stern-Volmer to experimentally obtained values of albumin 
fluorescence and from this determine the affinity constant. The 
fluorescence quenching data occurred through the drug binding 
with HSA at different temperatures and at different pH were 
analyzed according to the modified Stern–Volmer equation 
[23,24] 
( ) 11 1[ ]F F Q f K f
F F F
−− −= = +
∆ −
 

                   (1)
Where Fo and F are the relative fluorescence intensities of the 
protein in the absence and
presence of the quencher drug, respectively, ΔF is the difference 
in fluorescence intensity of Fo and F, f  is the fractional maximum 
fluorescence intensity and K is the effective quenching constant 
for the accessible fluorophores, which is analogous to the 
associative binding constant (Kass) for a quencher–acceptor 
system. The modified Stern-Volmer plots for the effect of 
temperature change have been shown in Figure 3. A good linear 
relationship between 
F
F
∆
   and 1][ −Q was observed, and the slopes 
were decreased with temperature, and the association constants 
were inversely correlated with temperature. The results assuming 
that the quenching process was static. 
Additionally, the fluorescence quenching data were analyzed at 
different pHs (6.0 -8.0) at the same temperature (25°C), and the 
corresponding association constants for the three studied drugs 
were presented in Table 1.  
Thermodynamic parameters (∆G°, ∆H°, and ∆S°) for drug-HSA 
interaction were determined for the three studied drugs at pH 
7.0 at four different temperatures (20, 25, 30 and 40°C).
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Figure 3 The ﬂuorescence quenching spectra of human serum albumin ( 1.5  μM )  
at various concentrations of drugs  ranged in  ranged in 0 - 0.42 µM: (a) DIC , (b) 
FUR  and (c) DEX  λex.= 278 nm and λem= 300-500 nm. T= 298 K, pH = 7.0 
The fluorescence quenching spectra of 
human seru  albumin ( 1.5  μM )  at various 
concentrations of drugs  ranged in  ranged in  
0 - 0.42 µM: (a) DIC , (b) FUR  and (c) DEX  λ
ex
.= 
278 nm and λem= 300-500 nm. T= 298 K, pH = 7.0 
Figure 3
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For both effects using the equations:
∆G° = - 2.303 RT log Kass.                                                (2)
log Kass =  -  ∆H°/ 2.303RT + ∆S°/ 2.303 R                    (3)
∆G° = ∆H°- T∆S°                    (4) 
The corresponding linear regression equations and results at 
four different temperatures (20-40°C) are shown in Figure 4 and 
Table 2. The results showed that the binding constants between 
the studied drugs and HSA were decreased with temperature, 
resulting in a reduction of the stability of the drug–HSA complex 
formed.
The spectral overlap curves as well as energy transfer parameter 
data were imported through Excel spreadsheet into MATLAB R 
213a program and then analyzed and visualized as shown in results 
and discussion. The imported measurements were integrated 
into an automated analysis workflow in MATLAB program using a 
written script to calculate the needed parameters.
Results and Discussion
The fluorescence spectra of HSA upon addition of drugs (DIC, 
FUR and DEX) used in this study were determined and have been 
shown in Figure 3. It is obvious that HSA fluorescence emission 
that is peaked at 340 nm was quenched after being excited with a 
wavelength of 278 nm as the drug concentrations increased. and 
there was a slight red shift at the maximum wavelength from 340 
to 344 nm, which suggested that there was interaction between 
the drug used and HSA forming drug-HSA complex, making a 
slight change in the environment around the chromophore of 
HSA and indicates that a slight conformational change may take 
place during the binding of the drugs with the HSA. Addition of 
the drug in question (DIC, FUR, and DEX) leads to quench the 
fluorescence emission spectra of HSA at 340 nm by variable 
extents, being the maximum quenching on addition of Diclofenac 
sodium drug.
Drug E J (cm-3M-1) R0 (nm) r (nm)
Diclofenac sodium 0.56 3.7011x10-14 3.1 2.98
Furosemide 0.26 1.0772x10-13 3.7 3.52
Dexamthasone 0.20 2.2468x10-13 4.2 5.30
Table 1 Energy transfer parameters for the interaction of drugs with human 
serum albumin.
  
 
 
0.0001 0.0002 0.0003 0.0004
0
5
10
15
20
25
30
35
 
 
F 0
/ ∆
F
1/[DIC],  M-1 
Figure 4 Modiﬁed Stern-Volmer plots for the three drugs; DIC, FUR and DEX. Each plot is made at four diﬀerent temperatures: (○20°C, □ 25°C, 
30°C, and  40°C).
Modified Stern-Volmer plots for the three drugs; DIC, FUR and DEX. Each plot is mad  at four different temperatures: (○20°C,  
□ 25°C, ●30°C, and  40°C).
Figure 4
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The binding constants (Kass)  were calculated using the modified 
Stern–Volmer equation (equation 1)  and the results were 
reported in Table 1. It was found that the interaction between 
the studied drugs (DIC, FUR and DEX) with HSA occur with 
variable affinities and the binding constants (Kass) for the studied 
drugs were decreased with increasing temperature as shown in 
Figure 4, confirming occurance of static quenching mechanisms 
in these interactions. 
Binding constants and effect of temperature
Using the fluorescence quenching data at different temperatures 
(20 - 40 °C) and at different pHs (6.0 – 8.0) the binding constants 
of the modified Stern-Volmer model analogous to association 
constants (Kass) for the binary complexes of each bound drug with 
HSA were calculated and listed in Table 2.
The association constants obtained in this study indicate that 
the affinity of these drugs toward HSA is similar to the affinity of 
other drugs and endogenous substances [25-27].
The decreasing trend of the association constants Kass with 
increasing temperature was in accordance with the KSV dependence 
on temperature, resulting in a reduction of the stability of the drug-
HSA complex.
The binding constants for the studied drugs with HSA were 
in the order of: KDIC > KFUR > KDEX. The affinity order for the 
binding constants among the three drugs studied towards HSA 
at all temperatures studied were explained by two factors 
acting together, firstly, the presence of carboxyl group in the 
drug chemical structure (for DIC and FUR) which is considered 
as the most reactive species toward albumin. This result was in 
agreement with previous findings for other drugs and endogenous 
substances that contain –COOH groups [25-27].
Secondly, the results can be explained on basis of n-octnol/water 
partition coefficient for these drugs which also follows the order 
: DIC > FUR > DEX. Hence, diclofenac sodium drug being the most 
hydrophobic molecule can penetrate the hydrophobic part of 
subdomain IIA in HSA more easily than the other two drugs.
Stern-Volmer constants which are analogous to binding constants 
for drug/HSA were calculated according to modified Stern-
Volmer (equation 1).   
The main HSA binding regions are located in subdomains IIA and 
IIIA as it results from crystallograghy study of X-ray diffraction for 
several ligands. 
The two subdomains (IIA and IIIA) in HSA have some structural 
differences that cause the drugs bind somewhat differently in the 
hydrophobic loop of the subdomain AII in HSA. The portion of 
the subdomain IIA that binds the hydrophobic part of the drug 
contains Trp 214 which plays the key role as a chromophore in 
such binding.
On the other hand, the dexamethasone drug (DEX) as a 
steroidal drug being a hydrophobic molecule can penetrate the 
hydrophobic subdomain IIA (in HSA)  into which the Trp 214 is 
located and showed the quenching effect to a lesser extent since 
it does not contain a carboxylic group as the previous drugs DIC 
and FUR.  
Thermodynamic parameters and nature of the 
binding forces
The human serum albumin fluorescence quenched due to 
increasing concentrations of the three drugs studied can indicate 
that the drugs interact with albumin in the surrounding of 
the albumin fluorescent residue tryptophan 214 localized in 
subdomain IIA. The binding of the drug molecule to albumin can 
affect its fluorescence by acting as a tryptophan quencher via 
collision between the two targets or via energy transfer. 
Generally, there are four types of noncovalent interactions 
that could play a major role in ligand binding to proteins. These 
are hydrogen bonds, van der Waals forces, electrostatic, and 
hydrophobic bond interactions [28]. The binding of the drugs in 
this study was accompanied by negative enthalpic and negative 
entropic contributions indicating that van der Waals interactions 
and hydrogen bonds played the major roles in the binding 
reaction [29]. 
Evaluation of thermodynamic parameters for each drug (DIC, 
FUR and DEX) with HSA, was carried out using equations 2-4 (as 
written in data and analysis). 
Inspection for the values in Table 2 reflects a decrease in the 
values of binding constant with temperature in the studied range. 
This thermodynamic stabilization of the drug-HSA complex with 
the increase in temperature can better be explained by the likely 
overall conformational whole structure of the conjugate formed 
rather than the additional local interaction.
 The values of ΔH° and ΔS° were calculated from the slope and 
intercept of the plot of 1n Kass versus 1/T, (respectively). The 
negative values of both ΔH° and ΔS° indicate that drug interactions 
with HSA were enthalpic driven and entropic unfavorable. The 
high negative enthalpy change value for the drug–HSA complex 
was just as the consequence of the interaction between the two 
negatively charged species at pH studied. 
The association constants obtained at different temperatures 
(20 – 40 ΔH°C) were treated thermodynamically to calculate the 
Temperature, K
Stern-Volmer constant (KSV) × 10-4, M-1
                  Diclofenac Sodium (DIC) Furosemide (FUR) Dexamethasone (DEX)
293 4.14 3.32 3.10
298 3.37 2.71 2.50
303 1.95 1.87 1.74
313 1.66 1.46 1.03
Table 2 Stern-Volmer binding constant Ksv for the HSA-drug system at pH 7.0 and at different temperatures; λex = 278 nm, λem = 250 – 500 nm.
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Thermodynamic
parameter
Diclofenac 
sodium Furosemide Dexamethasone
∆G° (kJmol-1) -25.83 -25.29 -25.09
∆H° (kJmol-1) -36.56 -32.10 -29.06
∆S° (Jmol-1) -36.66 -23.11 -15.80
Table 3 Thermodynamic parameters for the interaction of drugs (DIC, FUR 
and DEX)with human serum albumin
pH KDIC × 10-4 KFUR × 10-4 KDEX × 10-4
6.0 4.25 3.76 2.81
6.5 3.55 3.08 2.45
7.0 3.37 2.71 2.50
7.5 2.14 1.45 2.37
8.0 1.70 0.89 2.19
Table 4 Binding constants for Drug / HSA interaction at different pHs (6 -8) 
in phosphate buffer solution and at 25°C.
thermodynamic parameters (ΔG°ΔH°, and ΔS°for the studied drug-
HSA binding using equations 2-4. 
The negative values of ΔG° indicate that drug-HSA complexation 
is a spontaneous process. Thus the overall stability of drug-DNA 
complex is dictated by Gibbs free energy change (ΔG°) that involves 
both enthalpic and entropic contributions.
As seen from Table 3, both enthalpy and  entropy changes are 
negative suggested that Hydrogen bonding and van der Waals 
forces are the predominant forces that contribute to Gibbs free 
energy of the drug-HSA interaction.
Effect of pH on drug binding to HSA
The binding study of different concentrations of the studied drugs 
and the protein were performed at constant temperature (25°C) 
in phosphate buffer solutions of different pH values (6.0 – 8.0). A 
series of successive additions was made for selected drug to HSA 
as a function of pH and the data are presented in Table 4. The 
association constant at each pH was calculated as described before 
using the modified Stern–Volmer equation (equation 1).  
In the pH range at which the drug-HSA interaction was carried out, 
It is believed that both the donor and acceptor species in HSA and 
drug, respectively were in the anionic forms. The results suggest 
that the drug molecules become obstructed to penetrate the 
binding site in the subdomain IIA due to repulsion occurred.    
The energy transfer between the drug and HSA 
The importance of the energy transfer in biochemistry is that the 
efficiency of transfer can be used to evaluate the distance between 
the ligand and the tryptophan residues in the protein [30]. The 
fluorescence resonance energy transfer model (FRET) was used 
to determine the distance between the donor, Trp-214 residue in 
HSA and the acceptor bound drug. The efficiency of FRET model 
depends mainly on some factors which include: (i) the extent of 
spectral overlap between the donor emission and the acceptor 
absorption spectra, (ii) the orientation of the transition dipole 
of donor and acceptor species and (iii) the distance between the 
donor and acceptor species.
The distance between the donor and the acceptor can be 
calculated using FRET model. In which the efficiency of energy 
transfer, E, can be calculated by Equation 5 : 
( )6 6 60 0 01 / /E F F R R r= − = +                                                       (5)
Where F and F0 are the relative fluorescence intensities of the 
protein in presence and the absence of the drug, respectively, 
R0 is the distance at which the transfer efficiency equals 50%, 
and r is the distance between donor and acceptor.
6 25 2 4
0 8.8 10R k J n
− −= × Φ                                                     (6)
R0 is given by the following equation:
 Where n is the refractive index of the medium (n=1.36), k2 is 
the orientation factor (k2=2/3), φ is the quantum yield of the 
donor (φ = 0.14) [31] and J is the overlap integral between the 
donor emission and acceptor absorption spectra and is given by 
the following summation: 
( ) ( ) ( ) ( )4 /J F d F dλ λ ε λ λ λ λ λ=∑ ∑                                                     (7)
 The fluorescence quenching studies proved that HSA can form 
drug-protein complex, and suggest that the energy transfer 
between the studied drug and HSA occurred with various 
extents. The energy transfer effect is related not only to the 
distance between the acceptor and the donor, but also to the 
critical energy transfer distance. 
The values of J, R0, and r are given in Table 1 and the emission 
spectra for HSA and the absorption spectra of the studied 
drugs (DIC, FUR and DEX) under the experimental conditions 
are shown in Figure 5. The comparable values of r and R0 were 
in accordance with conditions of Förster's non-radiative energy 
transfer theory and indicated that the energy transfer from 
donor residue to acceptor drug occurs with high possibility.
The average distance of r between the donor fluorophore and 
the acceptor is less than 7 nm, and the fulfillment of the required 
condition 0.5 R0 < r <1.5 R0 suggests that the energy transfer 
from HSA to the drug used can occur with high probability. An 
average r distance on the 2-8 nm scale indicates that the energy 
transfer occurs with high probability [32-35] and in accordance 
with the prediction by Förster’s non-radiative energy.
Conclusion
In this paper, we investigated the interaction between three 
drugs (DIC, FUR and DEX) with HSA by fluorescence spectroscopy. 
The experimental results indicate that the probable quenching 
mechanism of fluorescence of HSA by these drugs is static 
quenching mechanism. The drugs can interact with HSA.
Diclofenac sodium drug bound more effectively than the other 
two drugs (FUR and DEX). Our results clarified that these drugs 
can interact with HSA spontaneously through van der Waals 
interactions and hydrogen bonds is in the hydrophobic pocket 
of the specific binding site.
The association constants of these drugs with HSA were in the 
order of 103 - 105 M-1, being decreased with temperature (20 
– 40°C). Hydrogen bonding and hydrophobic interactions are 
7© Under License of Creative Commons Attribution 3.0 License 
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Figure 5 Spectral overlap of the ﬂuorescence emission spectra of HSA with the absorption spectra of studied drugs: (a) DIC (b) FUR (c) 
DEX. The solid line is the ﬂuorescence emission of HSA, and the dashed line is the absorption spectrum of the drug used. [HSA] = 1 
µM, [drug] = 1.5 µM, T = 298 K.
Spectral overlap of the fluorescence emission spectra of HSA with the absorption spectra of studied drugs:  (a) DIC (b) FUR  
(c) DEX. The solid line is the fluoresce ce emissio  of HSA, and the dashed line is the absorption spectrum of the drug used. 
[HSA] = 1 µM, [drug] = 1.5 µM, T = 298 K.
Figure 5
involved through the binding process between the studied drugs 
and HSA. The distances between the drug molecule studied and 
HSA were between (3-5.5 nm) and were calculated using Förster’s 
energy transfer theory.
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